Lipoprotein(a) Biochemistry
On this page
Direct answer
Lipoprotein(a), or Lp(a), is an LDL particle to which a second glycoprotein, apolipoprotein(a), is attached by a disulfide bond to apo B-100. Apo(a) is structurally homologous to plasminogen, with multiple kringle IV repeats whose number — an inherited trait — sets the plasma concentration, so Lp(a) levels are essentially decided at birth. Because the kringle domains mimic plasminogen's fibrin-binding region, Lp(a) competes with plasminogen and tPA, impairs fibrinolysis, carries oxidised phospholipid, and behaves as both atherogenic and prothrombotic. Concentrations above roughly 50 mg/dL (about 125 nmol/L) mark an independent, genetically determined cardiovascular risk factor that is barely moved by statins.
What you must remember
- Structure: one LDL particle (apo B-100, cholesterol ester core) plus one apo(a) linked by a disulfide bridge; apo(a) is made in the liver and assembles with LDL extracellularly.
- Kringle IV copy number varies from person to person; smaller apo(a) isoforms with fewer kringle IV repeats correlate with higher plasma concentrations and higher risk.
- Risk threshold: values above about 50 mg/dL (over ~125 nmol/L in molar units — the two units are not interchangeable, so follow your laboratory's assay) roughly double cardiovascular risk; measurement need not be fasting.
- Genetically fixed: lifestyle and statins change Lp(a) little; niacin lowers it by up to roughly a third and PCSK9 inhibitors by about a fifth to a quarter, but no agent is approved yet specifically to lower Lp(a).
- Antisense and siRNA agents (pelacarsen, zerlasiran, olpasiran among them) lower Lp(a) substantially; the large pelacarsen outcomes trial reported in 2026 missed its primary cardiovascular endpoint, and outcome evidence for the class remains unsettled — a fast-moving field to quote with a date.
- When to suspect high Lp(a): premature myocardial infarction or stroke without conventional risk factors, familial hypercholesterolaemia (frequent co-traveller), aortic valve stenosis (Lp(a) is an identified risk marker), and unexplained high LDL refractory to statins.
- Confounding states: levels rise in nephrotic syndrome, chronic kidney disease and pregnancy; they fall in severe liver disease — interpret alongside albumin and LFTs.
A premature-MI work-through
A 38-year-old non-smoking man, lean and non-diabetic, survives an anterior wall myocardial infarction. His LDL is 150 mg/dL, HDL normal, and there is a strong history of early coronary disease in two uncles. The one measurement most often skipped in Indian clinics is Lp(a); ordered here, it returns 92 mg/dL. The interpretation writes itself: this is a genetically determined, lifelong exposure, his siblings each carry roughly a one-in-four chance of a similar level, and cascade screening of the family is justified once — a single measurement suffices for life because levels are stable. Management does not wait for Lp(a)-specific drugs: high-intensity statin therapy to drive LDL as low as possible (the risk of Lp(a) falls substantially when coexisting LDL burden is reduced), aspirin, risk-factor control, and lipoprotein apheresis in select countries for extreme values with recurrent events. He should also have an aortic valve surveillance echo, given the stenosis association.
How the examiner frames it
Two traps recur. The first: "statin therapy raised my patient's Lp(a) — what happened?" Statins can modestly increase Lp(a) percentage-wise while lowering absolute LDL; the net effect is strongly favourable, and this is a discussion point, never a reason to stop therapy. The second: units. Papers quote mg/dL and nmol/L interchangeably at students' peril, because apo(a) size makes conversion non-linear — always state which assay your lab reports. A third favourite is the plasminogen link: candidates who say "Lp(a) causes thrombosis by inhibiting fibrinolysis" score, those who say "it is just LDL" do not.
Frequently asked questions
What is the structural relationship between apo(a) and plasminogen?
Apo(a) shares homology with plasminogen, including kringle IV-like repeats, and competes with plasminogen for fibrin binding, impairing clot lysis.
At what level is Lp(a) considered high-risk?
Above approximately 50 mg/dL (about 125 nmol/L), with risk rising further in the top quintile; one lifetime measurement is sufficient.
Does statin therapy lower Lp(a)?
No — statins mainly lower LDL; any small Lp(a) rise is outweighed by benefit, so aggressive LDL lowering remains the treatment backbone.
Which non-lipid condition is associated with elevated Lp(a)?
Calcific aortic valve stenosis, where Lp(a)-associated oxidised phospholipids are deposited in the valve leaflets.
Should family members of a patient with high Lp(a) be tested?
Yes — because levels are inherited, cascade screening of first-degree relatives identifies others at premature cardiovascular risk.